Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaMedica TherapeuticsDMAC +6.13%31 Future 3-5Y EPS without NRI Growth Rate is -8.41 as of Sep. 22, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 411 Biotechnology companies, DiaMedica Therapeutics ranks worse than 80.05% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
DiaMedica Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms
DMAC vs SABS, AGEN, PALI: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of -8.41 mean?
DiaMedica Therapeutics (DMAC) has a Future 3-5Y EPS without NRI Growth Rate of -8.41 as of Sep. 22, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #329 out of 411 companies in the Biotechnology industry, placing it in the top 80%.
Is DiaMedica Therapeutics' Future 3-5Y EPS without NRI Growth Rate too high?
DiaMedica Therapeutics' current Future 3-5Y EPS without NRI Growth Rate is -8.41. Based on the distribution chart, DiaMedica Therapeutics ranks #329 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Future 3-5Y EPS without NRI Growth Rate compare to SABS and AGEN?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #329 out of 411 companies for Future 3-5Y EPS without NRI Growth Rate. This places DiaMedica Therapeutics in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 22.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Biotechnology company?
The median Future 3-5Y EPS without NRI Growth Rate among Biotechnology companies is 22.02, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for DiaMedica Therapeutics and its competitors. For the Biotechnology industry, the median Future 3-5Y EPS without NRI Growth Rate is 22.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DiaMedica Therapeutics's current Future 3-5Y EPS without NRI Growth Rate is -8.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Future 3-5Y EPS without NRI Growth Rate of -8.41. The current Future 3-5Y EPS without NRI Growth Rate is -8.41. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Future 3-5Y EPS without NRI Growth Rate is -8.41 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in the United States that develops treatments for ischemic and inflammatory diseases. Its lead product candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, a protease enzyme that regulates blood flow and inflammation; it is being developed for acute ischemic stroke and preeclampsia. The company's earlier-stage pipeline includes DM300, a recombinant human ulinastatin, a broad-spectrum serine protease inhibitor being explored as a potential therapy for severe acute pancreatitis. DiaMedica does not yet market approved products and generates no product revenue, funding its research and clinical development through equity financings and other capital-raising activities. Its activities are centered on conducting clinical trials in the United States and other jurisdictions, with a focus on addressing conditions that have limited or no approved treatment options.
31GF Score
Get the complete analysis for DMAC
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
